Acceleron Pharma (XLRN) Misses Q3 EPS by 2c

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.55), $0.02 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.08 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• SPAR Group (SGRP) Reports Q2 EPS of $0.04
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance